A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)

Recruiting

Phase 1

MK-4716A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)

Sponsor:

Merck Sharp & Dohme LLC

Code:

NCT07247110

Conditions

Malignant Neoplasm

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

MK-4716

Pembrolizumab

Cetuximab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-01-09. This information was provided to ClinicalTrials.gov by Merck Sharp & Dohme LLC on 2025-12-30.